Samsung Biologics has entered into an agreement with GlaxoSmithKline to acquire 100 percent of the Human Genome Sciences manufacturing facility in Rockville, Maryland, for $280 million, marking the company’s first U.S.-based drug production site and a major expansion of its global footprint.
The acquisition is being made through Samsung Biologics America, a wholly owned U.S. subsidiary of the South Korea-based contract development and manufacturing organisation. Closing is anticipated in early 2026.
The Rockville facility includes two Current Good Manufacturing Practices plants with a combined drug substance capacity of 60,000 liters, supporting clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, while Samsung Biologics plans additional investments to expand capacity and upgrade technology to strengthen the U.S. supply chain for critical biologic medicines.
More than 500 employees currently at the facility will be retained to ensure operational continuity and stability. Integrating the site into Samsung Biologics’ global network will provide clients with flexible, multi-site manufacturing options across the U.S. and Korea, ensuring reliable availability of life-saving therapeutics for patients.
Samsung Biologics currently operates five plants with a combined capacity of 785,000 liters and maintains commercial offices in Korea, the U.S., and Japan. Its portfolio spans monoclonal antibodies, antibody-drug conjugates, mRNA products, organoid-based services, and next-generation therapies, reinforcing its position as a leading global contract development and manufacturing organisation.
The acquisition also supports GSK’s strategic goals by securing domestic manufacture of two critical medicines and enhancing supply chain resilience, complementing GSK’s broader $30 billion investment in U.S. R&D and manufacturing over the next five years.
Also Read